Argenx Se (ARGX) Receivables - Net (2015 - 2026)
Argenx Se's (ARGX) quarterly Receivables - Net came in at $1.9 billion in Q2 2026, down 99.84% YoY from $1197.1 billion in Q2 2025, and up 17.24% on a QoQ basis from $1.6 billion in Q4 2025.
Argenx Se (ARGX) Receivables - Net (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Receivables - Net data on file, last reported at $1.9 billion in Q2 2026.
- Quarterly Receivables - Net fell 99.84% year-over-year to $1.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 billion (down 99.84% YoY) and the FY2025 annual result came in at $1.6 billion, up 82.1% from the prior year.
- Receivables - Net grew to $1.9 billion in Q2 2026, from $1.6 billion in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $1197.1 billion in Q2 2025 to a low of $112.4 million in Q2 2022.
- A 5-year average of $133.7 billion and a median of $652.9 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2025 — Receivables - Net soared 183253.63% — and 2026, when it slumped 99.84%.
- Tracing ARGX's Receivables - Net over 5 years: stood at $275.7 million in 2022, then soared by 80.16% to $496.7 million in 2023, then soared by 82.1% to $904.5 million in 2024, then surged by 82.1% to $1.6 billion in 2025, then advanced by 17.24% to $1.9 billion in 2026.
- The last three Receivables - Net figures came in at $1.9 billion (Q2 2026), $1.6 billion (Q4 2025), and $1197.1 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.93 Bn |
| Jun 30, 2026 | 1.93 Bn |
| Dec 31, 2025 | 1.65 Bn |
| Dec 31, 2025 | 1.65 Bn |
| Jun 30, 2025 | 1,197.07 Bn |
| Jun 30, 2025 | 1,197.07 Bn |
| Dec 31, 2024 | 904.47 Mn |
| Dec 31, 2024 | 904.47 Mn |
| Jun 30, 2024 | 652.88 Mn |
| Jun 30, 2024 | 652.88 Mn |
| Dec 31, 2023 | 496.69 Mn |
| Dec 31, 2023 | 496.69 Mn |
| Jun 30, 2023 | 353.23 Mn |
| Jun 30, 2023 | 353.23 Mn |
| Dec 31, 2022 | 275.70 Mn |
| Dec 31, 2022 | 275.70 Mn |
| Jun 30, 2022 | 112.39 Mn |
| Jun 30, 2022 | 112.39 Mn |
| Dec 31, 2021 | 38.22 Mn |
| Dec 31, 2021 | 38.22 Mn |